LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) — The Portnoy Law Firm notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Unicycive common stock between December 29, 2025 and June 29, 2026, inclusive (the ‘Class Period’). Find out if you qualify to recover your per-share losses by choosing to join the class action and submit your trade details. Investors who suffered financial losses have until November 2, 2026 to seek appointment as lead plaintiff. Shareholders should contact Lesley Portnoy via e-mail (Lesley@portnoylaw.com or call (310) 692-8883) or visit http://portnoylaw.com/unicycive-therapeutics-inc to learn more information and discuss their legal rights.
Please visit our website for more information on how to participate in this class action.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) that there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) that, as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHY PORTNOY LAW FIRM
The Portnoy Law Firm represents investors in complex securities class action litigation and shareholder rights matters across the nation. Founded by Lesley Portnoy, the firm’s attorneys have recovered billions of dollars for aggrieved institutional and retail investors. The firm leverages extensive legal expertise and sophisticated financial forensic capabilities to hold public corporations accountable for corporate wrongdoing and misrepresentation.
Lead Plaintiff Deadline: Investors who suffered losses on Unicycive Therapeutics, Inc. stock during the Class Period have until November 2, 2026 to seek appointment as lead plaintiff.
Frequently Asked Questions About the Unicycive Lawsuit
Q: What is the Unicycive lead plaintiff deadline?
A: The deadline to apply for lead plaintiff appointment is November 2, 2026. This deadline applies strictly to investors seeking to serve as lead plaintiff representing the class. Class members who do not apply may still participate in any eventual financial recovery as absent class members without taking any action at this time.
Q: How much did Unicycive stock drop and on what dates?
A: Following the public disclosure on June 30, 2026, that the FDA had issued a second Complete Response Letter (CRL) regarding the resubmitted New Drug Application (NDA) for oxylanthanum carbonate (OLC)—identifying the exact same third-party manufacturing deficiencies as the previous CRL—Unicycive’s stock price fell $3.01 per share, or 39.1%, to close at $4.69 per share on June 30, 2026, on unusually heavy trading volume.
Q: What specific misstatements does the Unicycive lawsuit allege?
A: The lawsuit alleges that Unicycive Therapeutics, Inc. and its executive officers misled investors by touting the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) and claiming that its third-party manufacturing vendor had made significant progress toward regaining FDA compliance. Specifically, the complaint asserts that these statements were materially false and misleading because Defendants failed to disclose that the company had not actually inspected or audited its third-party manufacturing vendor’s facility to ensure compliance with current good manufacturing practices (cGMP). Consequently, the company lacked a reasonable basis to believe the vendor had resolved the FDA’s previously cited deficiencies, meaning the regulatory approval of OLC was subject to undisclosed risks of delay.
Q: What do Unicycive investors need to do right now?
A: Investors who purchased UNCY common stock during the Class Period (December 29, 2025 through June 29, 2026) should gather their trade confirmation slips or brokerage transaction logs showing purchase dates, number of shares, and prices paid. You may submit your trade details to Portnoy Law Firm here for a free, no-obligation evaluation of your potential loss recovery. No immediate legal action is required to remain an eligible absent class member.
Q: What is a lead plaintiff and why does it matter?
A: A lead plaintiff is a court-appointed class member who acts on behalf of all other class members in directing the litigation. The lead plaintiff is typically the investor or group of investors that makes a motion with the largest financial interest in the relief sought. While serving as lead plaintiff does not increase an investor’s individual financial recovery compared to other class members, it gives the investor direct authority to select lead counsel and oversee the prosecution of the lawsuit.
Q: Does the lead plaintiff receive any type of compensation?
A: Yes, in many cases, Courts award the lead plaintiff an additional amount of money to compensate the lead plaintiff for their participation in the case.
Q: Does it cost anything to participate in this case as a lead plaintiff?
A: A lead plaintiff does not pay any fees or expenses out of pocket. Our firm works on a contingency basis, and will collect any fees or expenses directly from a future recovery.
Q: What if I already sold my Unicycive shares — can I still recover losses?
A: Yes. Eligibility to participate in a securities class action recovery depends on whether you purchased or acquired UNCY common stock during the Class Period (December 29, 2025 to June 29, 2026) and suffered an economic loss. Investors who sold their shares prior to or after the public disclosures may still be eligible to recover damages based on the artificial inflation present in the stock at the time of purchase.
Q: How long will the Unicycive lawsuit take to resolve?
A: Securities class action lawsuits typically take between two and four years from initial filing to full resolution. The exact timeline depends on court scheduling, motion practice (such as motions to dismiss), pre-trial discovery, and potential settlement negotiations or trial proceedings.
Q: Can I choose a different law firm to represent me?
A: Yes. Investors have the absolute right to retain any legal counsel of their choice. When multiple class action complaints are filed, the court will consolidate the actions and appoint a lead plaintiff and lead counsel. You may choose to be represented by Portnoy Law Firm, retain separate counsel, or remain an absent class member represented by court-appointed lead counsel.
CONTACT INFORMATION
Portnoy Law Firm
Lesley Portnoy, Esq.
Email: lesley@portnoylaw.com / info@portnoylaw.com
Telephone: (310) 692-8883
Attorney Advertising. Prior results do not guarantee a similar outcome.
Media gallery
